Ponezumab

Monoclonal antibody

^NY (what is this?) (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.^[1]^[2]

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.^[3]

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
^ Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
^ "Alzforum".

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†